Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions
OXFORD, United Kingdom, March 20, 2023 (GLOBE NEWSWIRE) --
Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company
focused on the development of novel T cell immunotherapeutics designed
to use the power of the immune system to potentially treat and cure
chronic infectious diseases, autoimmune diseases and cancer, today
announced topline interim data from the HPV001 study (NCT04607850), a Phase 1b/2 clinical trial of VTP-200 in women with low-grade cervical human papillomavirus (HPV) lesions.
More info >> |
